State Street Corp grew its position in Xencor Inc (NASDAQ:XNCR) by 58.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,160,578 shares of the biopharmaceutical company’s stock after acquiring an additional 799,664 shares during the quarter. State Street Corp owned about 3.81% of Xencor worth $72,876,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. BlackRock Inc. grew its holdings in shares of Xencor by 5.2% during the second quarter. BlackRock Inc. now owns 4,324,181 shares of the biopharmaceutical company’s stock worth $176,988,000 after buying an additional 213,329 shares in the last quarter. EcoR1 Capital LLC grew its position in shares of Xencor by 13.5% in the second quarter. EcoR1 Capital LLC now owns 2,336,557 shares of the biopharmaceutical company’s stock valued at $95,635,000 after purchasing an additional 277,128 shares in the last quarter. Northern Trust Corp grew its position in shares of Xencor by 1.0% in the second quarter. Northern Trust Corp now owns 611,797 shares of the biopharmaceutical company’s stock valued at $25,040,000 after purchasing an additional 5,796 shares in the last quarter. Marshall Wace LLP increased its holdings in shares of Xencor by 1,320.1% in the second quarter. Marshall Wace LLP now owns 364,291 shares of the biopharmaceutical company’s stock valued at $14,910,000 after purchasing an additional 338,639 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its holdings in shares of Xencor by 3.0% in the second quarter. Charles Schwab Investment Management Inc. now owns 279,034 shares of the biopharmaceutical company’s stock valued at $11,421,000 after purchasing an additional 8,045 shares during the last quarter. Institutional investors and hedge funds own 92.43% of the company’s stock.
XNCR has been the topic of a number of recent research reports. Mizuho reissued a “buy” rating on shares of Xencor in a research note on Tuesday, November 5th. ValuEngine cut Xencor from a “strong-buy” rating to a “buy” rating in a report on Saturday. Leerink Swann cut their target price on Xencor from $52.00 to $44.00 and set an “outperform” rating for the company in a research note on Wednesday, November 6th. Zacks Investment Research lowered Xencor from a “buy” rating to a “hold” rating in a report on Saturday, November 16th. Finally, BidaskClub raised shares of Xencor from a “buy” rating to a “strong-buy” rating in a research report on Saturday. One investment analyst has rated the stock with a sell rating, three have given a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. Xencor presently has an average rating of “Buy” and a consensus price target of $43.90.
Xencor (NASDAQ:XNCR) last announced its quarterly earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($0.18) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.58) by $0.40. The business had revenue of $21.76 million for the quarter, compared to analyst estimates of $4.62 million. Xencor had a return on equity of 5.84% and a net margin of 21.60%. As a group, sell-side analysts anticipate that Xencor Inc will post 0.5 EPS for the current year.
Xencor Company Profile
Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and other protein therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions.
Featured Story: Growth Stocks, What They Are, What They Are Not
Want to see what other hedge funds are holding XNCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xencor Inc (NASDAQ:XNCR).
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.